BioCentury
ARTICLE | Clinical News

Catalyst climbs on Firdapse readout in rare form of MG

March 15, 2017 5:05 PM UTC

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) jumped $0.38 (32%) to $1.55 on Wednesday after it said Firdapse amifampridine phosphate met the co-primary endpoints in a Phase II/III trial to treat myasthenia gravis in patients with anti-muscle associated receptor tyrosine kinase (MUSK) antibodies (MUSK-MG). Catalyst CEO Patrick McEnany told BioCentury that the company hopes to meet with FDA next quarter to discuss a registration trial.

MUSK-MG is a rare form of MG found predominantly in females. According to Catalyst, there are no drugs approved in the U.S. for MUSK-MG...